A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910